Article Text

Download PDFPDF

LP-150 Outcomes of serologically active clinically quiescent (SACQ) versus serologically and clinically quiescent (SQCQ) statuses in patients with systemic lupus erythematosus
  1. Rattapol Pakchotanon and
  2. Chonlamark Rattanakom
  1. Department of Medicine, Phramongkutklao College of Medicine, Thailand


Background To compare the prognosis of SLE patients who achieve clinically quiescent following treatment, with or without serologically active.

Methods We categorized SLE patients from Lupus Clinic of Royal Thai Army (LUCRA) cohort based on disease activity status (DAS): serologically active clinically quiescent (SACQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) without serological domain = 0, positivity of anti-dsDNA or low complement; serologically and clinically quiescent (SQCQ) patients, SLEDAI-2K = 0. Prednisolone ≤ 5 mg/day, immunosuppressive drugs and antimalarials were allowed. Those who were not in any remission definitions were defined as non-remission status. Outcomes included flare (any new clinical feature of the SLEDAI-2K) and increase in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) overtime. Regression analysis models were constructed to identify predictors of the outcomes.

Results A total of 197 patients with SLE were evaluated between March 2017 and November 2022. Sixty-eight SACQ patients, 57 SQCQ patients, and 72 non-remission patients were identified. The mean ± SD of follow up was 4.79 ± 0.63 years. The percentage of flares over 3 years after achieving SACQ status was 50% versus 26.3% in SQCQ (p = 0.007), and over 5 years was 57.4% versus 35.1%, respectively (p = 0.013). However, the changes in SDI over 5 years were similar between SACQ, SQCQ, and non-remission patients (22.9%, 24.8%, and 21.5%, respectively), p= 0.87. In addition, multivariable analysis revealed that SACQ status was not independent risk factor for increasing flare event compared with SQCQ group when adjusting for confounding factors (HR 1.65; 95% CI:0.94–2.89; p=0.083).

Conclusions To attain serologically remission in patients with clinically quiescent SLE had similar effects on flare event and damage accrual compared to serologically active. This supports treating SLE with a treat-to-target strategy for achieving clinical remission, irrespectively of serological activity.

  • treat-to-target
  • autoantibodies
  • flare

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.